Hormonal contraceptive Access via Pharmacist-Prescribing Implementation package (HAPPI)

通过药剂师处方获取激素避孕药实施包 (HAPPI)

• 批准号: 10385525
• 负责人: Ashley H Meredith
• 金额: $ 24.35万
• 依托单位: EMPOWERX, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-30 至 2023-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10385525
• 关键词: Hormonal; contraceptive; Access; via; Pharmacist

Project Summary/Abstract With 95% of unintended pregnancies in the United States attributed to incorrect, inconsistent, or non-use of contraception, improving access to reliable contraception is an important public health issue. Pharmacists are considered the most accessible health care provider and are well-positioned to improve contraception access by providing pharmacist- prescribed contraception services. The focus of this proposed work is on pharmacists who can provide greatest access – those in community pharmacies. There are more than 67,750 community pharmacies in the United States and only 3,500 are currently offering pharmacist prescribing of contraception. Research consistently identifies barriers to implementation of pharmacist contraception prescribing. In order to maximize access to contraception, barriers to pharmacist implementation must be addressed. This project will develop a Hormonal contraceptive Access via Pharmacist-Prescribing Implementation (HAPPI) package that will support effective and sustainable provision of pharmacist-prescribed contraception services. We will use a convergent, parallel design including both quantitative and qualitative data, grounded in implementation science using the Consolidated Framework for Implementation Research (CFIR) and Evidence-Based Quality Improvement (EBQI). The mixed methods approach will better inform development and refinement of the HAPPI package. A summary of the existing technology, tools, and resources that may be used, needed, and/or considered to overcome frequently cited barriers to the implementation of pharmacist-prescribed contraception services will be created. Model adopter case studies will be created to illustrate “best practices”. Pharmacy decision makers (owners and executives) and end-users (pharmacy manager pharmacists and staff pharmacists) will participate in focus groups for concept mapping and a multi-stakeholder advisory panel. The focus groups will identify and prioritize tools and resources to be included in the HAPPI package while the multi-stakeholder advisory panel will provide input on perceived acceptability, appropriateness, and feasibility of implementing pharmacist-prescribed contraception services with and without the HAPPI package. Pharmacist contraceptive prescribing has the potential to expand access to contraception. If successful, this project will create a prototype implementation package that will form the basis for our future SBIR Phase II grant to conduct usability testing and ultimately commercialize and measure the impact of the HAPPI package.

项目总结/摘要 在美国，95%的意外怀孕归因于不正确的， 不一致或不使用避孕药具，改善获得可靠避孕药具的机会是一个 重要的公共卫生问题。药店被认为是最容易获得的医疗保健 提供者，并有能力通过提供药剂师来改善避孕药具的获得， 提供避孕服务。这项拟议工作的重点是药剂师谁可以 提供最大的获取机会--社区药房。有超过67，750个 目前，美国只有3,500家社区药房提供药剂师服务， 避孕的处方。研究一致确定了实施 药剂师避孕处方。为了最大限度地获得避孕药具， 药剂师的问题必须解决。 该项目将开发一种通过药剂师处方获得的激素避孕药 执行（HAPPI）一揽子计划，将支持有效和可持续地提供 药剂师处方的避孕服务。我们将使用一个收敛的平行设计 包括定量和定性数据，以执行科学为基础， 实施研究（CFIR）和循证质量综合框架 改善（EBQI）。混合方法将更好地为开发提供信息， HAPPI包的改进。现有技术、工具和资源的摘要 可用于、需要和/或考虑克服经常提到的 将建立药剂师处方避孕服务。模型采用者 将进行个案研究，以说明“最佳做法”。药房决策者（业主 和行政人员）和最终用户（药房经理药剂师和工作人员药剂师）将 参加概念规划重点小组和多利益攸关方咨询小组。的 焦点小组将确定并优先考虑将包括在HAPPI包中的工具和资源 虽然多方利益攸关方咨询小组将提供关于可接受性的意见， 实施药剂师处方避孕服务的适当性和可行性 无论是否使用HAPPI软件包。 药剂师避孕处方有可能扩大获得 避孕。如果成功，该项目将创建一个原型实施包， 形成我们未来SBIR第二阶段拨款的基础，以进行可用性测试， 商业化和衡量HAPPI包的影响。